All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @tucirujanobariatra on TikTok · 8s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @tucirujanobariatra's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It is always nice to see you says the

@tucirujanobariatra's GLP-1 side effects, fact-checked

Dr. Alejandro Zúñiga

TikTok creator

707.6K viewsWatch on TikTok →

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and slow gastric emptying. The STEP 1 trial showed 14.9% weight loss with semaglutide 2.4mg, but 44% of patients experienced nausea compared to 17% on placebo.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @tucirujanobariatra's GLP-1 side effects, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Video claim decision path

Turn the claim into a safer next question

Direct answer

@tucirujanobariatra's GLP-1 side effects, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Start the provider review

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@tucirujanobariatra's GLP-1 side effects, fact-checked" from Dr. Alejandro Zúñiga. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and slow gastric emptying.

The reason this review is not generic is the source wording and the canonical claim label "glp1 has experimentado alguno de estos efectos." In this clip, the useful excerpt is: "It is always nice to see you says the" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Gallbladder disorders occurred in 2.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and slow gastric emptying.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and slow gastric emptying. The STEP 1 trial showed 14.9% weight loss with semaglutide 2.4mg, but 44% of patients experienced nausea compared to 17% on placebo.
  • 44% of semaglutide patients experienced nausea in the STEP 1 trial compared to 17% on placebo
  • Gallbladder disorders occurred in 2.6% of patients versus 1.2% on placebo in clinical trials

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • 44% of semaglutide patients experienced nausea in the STEP 1 trial compared to 17% on placebo
  • Gallbladder disorders occurred in 2.6% of patients versus 1.2% on placebo in clinical trials
  • Pancreatitis, while rare at 0.2%, is still more common than the 0% rate seen with placebo
  • Starting at 0.25mg and titrating slowly reduces the severity of gastrointestinal side effects
  • About 5-10% of patients can't tolerate GLP-1 medications even with careful dose escalation
  • The STEP 1 trial showed 14.9% weight loss at 68 weeks, which often outweighs side effect risks
  • Animal studies showed thyroid C-cell tumors, leading to a black box warning for human use

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

Dr. Alejandro Zúñiga's TikTok about GLP-1 side effects has racked up over 700,000 views, but without seeing the video content, we can still address what patients typically experience with these medications.

What do we actually know about GLP-1 side effects?

The most common side effects are gastrointestinal. The STEP 1 trial (Wilding et al., NEJM, 2021) found that 44% of semaglutide patients experienced nausea compared to 17% on placebo.

Vomiting occurred in 24% versus 6%, and diarrhea in 30% versus 16%. These numbers matter because they're not rare occurrences. Most patients will experience at least some GI upset, especially during dose escalation.

The SURPASS-1 trial (Rosenstock et al., Lancet, 2021) showed similar patterns with tirzepatide. At the 15mg dose, 31% experienced nausea and 23% had diarrhea.

Are there more serious risks people should know about?

Yes, and this is where many TikTok creators fall short. Pancreatitis, while rare, occurred in 0.2% of semaglutide patients in clinical trials versus 0% in placebo groups.

Gallbladder problems are another concern. The STEP trials found gallbladder disorders in 2.6% of semaglutide patients compared to 1.2% on placebo. That's more than double the risk.

Thyroid C-cell tumors appeared in animal studies, leading to a black box warning. We don't have long-term human data spanning decades to fully understand this risk.

What about the psychological and social effects?

This is where the conversation gets complicated. Some patients report feeling less interested in food generally, not just overeating.

A small study by Bahji et al. (2022) suggested reduced alcohol cravings in some patients, though this wasn't the primary endpoint. The mechanism makes sense since GLP-1 receptors exist in reward pathways.

But we're still learning about these broader behavioral changes. The clinical trials focused on weight loss and glycemic control, not comprehensive quality of life measures.

How should patients actually think about these risks?

Context matters enormously. The STEP 1 trial showed 14.9% weight loss at 68 weeks, which can be life-changing for people with obesity-related health conditions.

Most side effects are dose-dependent and improve over time. Starting at 0.25mg semaglutide and titrating slowly reduces the severity of GI symptoms.

But patients need realistic expectations. About 5-10% of people can't tolerate these medications even with slow dose escalation. The benefits are real, but so are the side effects for many people.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Alejandro Zúñiga · TikTok creator

707.6K views on this video

Has experimentado alguno de estos efectos 👀

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 44% of semaglutide patients experienced nausea in the step 1?

44% of semaglutide patients experienced nausea in the STEP 1 trial compared to 17% on placebo

What does the video say about gallbladder disorders occurred in 2.6% of patients versus 1.2% on?

Gallbladder disorders occurred in 2.6% of patients versus 1.2% on placebo in clinical trials

What does the video say about pancreatitis, while rare at 0.2%,?

Pancreatitis, while rare at 0.2%, is still more common than the 0% rate seen with placebo

What does the video say about starting at 0.25mg?

Starting at 0.25mg and titrating slowly reduces the severity of gastrointestinal side effects

What does the video say about about 5-10% of patients can't tolerate glp-1 medications even with?

About 5-10% of patients can't tolerate GLP-1 medications even with careful dose escalation

What does the video say about the step 1 trial showed 14.9% weight loss at 68?

The STEP 1 trial showed 14.9% weight loss at 68 weeks, which often outweighs side effect risks

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. Alejandro Zúñiga, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.